Form D · Pharmaceuticals

Mayne Pharma Group Ltd

Melbourne, Victoria, C3 · CIK 0001560183

Offering snapshot reported Feb 8, 2013 · SEC filing

Reported sold
$142K
Offering amount: $347K
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 24, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 8, 2013Initial$141,770No comparison14SEC filing
Oct 12, 2012Initial$2,705,000No comparison14SEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-191550

Source: Form D, filed Feb 8, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ron Best Director
Mark Cansdale Executive
Vince Caretti Executive
Roger Corbett Director
Stefan Cross Executive
Andrew Dunbar Executive
Phil Hodges Director, Executive
Stefan Lukas Executive
Bruce Mathieson Director
Richard Moldin Executive
Stuart Mudge Executive
Scott Richards Director, Executive
Ian Scholes Director
Christelle Simpson Executive
Phillip Tindall Executive
Peter Truelove Executive
Brenton Walter Executive
Leigh Willis Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
Level 14 474 Flinders Street
Melbourne, Victoria, C3, 3000